Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary

Alexandra Leary; Purificación Estévez-García; Renaud Sabatier; Isabelle Ray-Coquard; Margarita Romeo; Pilar Barretina-Ginesta; Marta Gil-Martin; Elena Garralda; Joaquim Bosch-Barrera; Teresa Morán; Paloma Martin-Martorell; Ernest Nadal; Pere Gascón; Jordi Rodon; Jose M Lizcano; Pau Muñoz-Guardiola; Gemma Fierro-Durán; Oriol Pedrós-Gámez; Héctor Pérez-Montoyo; Marc Yeste-Velasco; Marc Cortal; Antonio Pérez-Campos; Jose Alfon; Carles Domenech; Alejandro Pérez-Fidalgo; Ana Oaknin

doi:10.1186/s12885-024-12700-0

Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary

BMC Cancer. 2024 Jul 29;24(1):911. doi: 10.1186/s12885-024-12700-0.

Authors

Alexandra Leary¹, Purificación Estévez-García², Renaud Sabatier³, Isabelle Ray-Coquard⁴, Margarita Romeo⁵, Pilar Barretina-Ginesta⁶, Marta Gil-Martin⁷, Elena Garralda⁸, Joaquim Bosch-Barrera⁶, Teresa Morán⁵, Paloma Martin-Martorell⁹, Ernest Nadal⁷, Pere Gascón¹⁰, Jordi Rodon¹¹, Jose M Lizcano^{12

13}, Pau Muñoz-Guardiola^{12

14}, Gemma Fierro-Durán¹⁴, Oriol Pedrós-Gámez¹⁴, Héctor Pérez-Montoyo¹⁴, Marc Yeste-Velasco¹⁴, Marc Cortal¹⁴, Antonio Pérez-Campos¹⁴, Jose Alfon¹⁴, Carles Domenech¹⁵, Alejandro Pérez-Fidalgo^#⁹, Ana Oaknin^#⁸

Affiliations

¹ Medical Oncology, Institut Gustave Roussy, Villejuif, France.
² Medical Oncology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
³ Department of Medical Oncology, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, Marseille, France.
⁴ Medical Oncology, Centre Léon Bérard, Lyon, France.
⁵ Department of Medical Oncology, Department of Medicine, Institut Català d'Oncologia Badalona Hospital Germans Trias i Pujol, Badalona-Applied Research Group in Oncology, Germans Trias i Pujol Institute, Universitat Autònoma de Barcelona, Badalona, Spain.
⁶ Medical Oncology Department, Precision Oncology Group (OncoGIR-Pro) Girona Biomedical Research Institute (IDIBGI) and Department of Medical Sciences, Institut Català d'Oncologia (ICO), Medical School University of Girona (UdG), Girona, Spain.
⁷ Medical Oncology, Catalan Institute of Oncology and IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.
⁸ Medical Oncology Service, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
⁹ Medical Oncology, INCLIVA-Hospital Clínico Universitario, Valencia, Spain.
¹⁰ Medical Oncology Service, Hospital Clínic. Universitat de Barcelona, Barcelona, Spain.
¹¹ Early Drug Development, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
¹² Department of Biochemistry and Molecular Biology, Institut de Neurocièncias, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Barcelona, Spain.
¹³ Protein Kinases in Cancer Research, Vall Hebron Institut de Recerca (VHIR), Barcelona, Spain.
¹⁴ Research and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain.
¹⁵ Research and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain. [email protected].

^# Contributed equally.

No abstract available

Publication types

Published Erratum